Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06153966 · ClinicalTrials.gov registry record · Phase 1
PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717
A Phase 1 study of Prion Disease, sponsored by Ionis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 13
- Study locations
NCT06153966: Recruiting Phase 1 study of Prion Disease, sponsored by Ionis Pharmaceuticals.
NCT06153966 is a Phase 1 study of Prion Disease that is actively recruiting participants, run by Ionis Pharmaceuticals. The registered enrollment target is 76 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% higher). The trial reports 13 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06153966, a Phase 1 study of Prion Disease, is actively recruiting participants, sponsored by Ionis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ION717
Study Locations (13)
Other
- Royal Melbourne Hospital - Parkville
- Hôpital Universitaire Pitié Salpêtrière - Paris
- University Medical Center Göttingen - Göttingen
- Tel Aviv Sourasky Medical Center - Tel Aviv
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta - Milan
- Hospital Clinic De Barcelona - Barcelona
Massachusetts
- Massachusetts General Hospital - Boston
New York
- NYU Langone Health - New York
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Quebec
- McGill University Health Centre - Montreal
Isesaki-shi
- Mihara Memorial Hospital - Gunma
Kodaira-shi
- National Center of Neurology and Psychiatry - Tokyo
Shimonoseki-shi
- Neuromuscular Center Yoshimizu Hospital - Yamaguchi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2024-01-04 |
| Est. Completion | 2030-06 |
| Phase | Phase 1 |
What NCT06153966 shows while recruiting
NCT06153966 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% higher).
The record links to 1 condition, with Prion Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06153966 lists 13 locations in 8 states (Other, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT06153966 about?
NCT06153966 is a clinical study titled "PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.
What is the current status of trial NCT06153966?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2024-01-04. Estimated completion is 2030-06.
What conditions does trial NCT06153966 study?
This clinical trial studies the following conditions: Prion Disease.
What interventions are being tested in trial NCT06153966?
The interventions under investigation include: Placebo (DRUG), ION717 (DRUG).
Who is sponsoring clinical trial NCT06153966?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06153966 being conducted?
This trial has 13 study locations across Massachusetts, New York, Ohio, Quebec, Isesaki-shi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06153966's enrollment target sits among peer trials
76 705th of 2000 higher than 1,290 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI